Glaucoma Update 2026: Management of Routine and Complex Glaucoma Cases

Originally Presented: Saturday, February 7, 2026

Wills Eye Auditorium

Conference Description:
We will address different approaches to challenging surgical and clinical glaucoma cases. We will also discuss new and evolving surgical techniques and devices and updates to clinical care. Presentations will cover ways to integrate advanced surgical techniques into the management of complex glaucoma cases using current guidelines and best practices. We will discuss and evaluate new and emerging glaucoma devices and treatment modalities for appropriate clinical integration.

At the conclusion of the course, participants should be able to:
1 Integrate advanced surgical techniques into the management of complex glaucoma cases.
2 Assess and manage complex clinical glaucoma presentations using current guidelines and best practices.
3 Evaluate new and emerging glaucoma devices and treatment modalities for appropriate clinical integration.

Accreditation Statement:
The Wills Eye Hospital is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Statement Designation:
Wills Eye Hospital designates this Live Activity for a maximum of 3.50 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement:
It is the policy of Wills Eye Hospital that the information presented at Wills Eye Hospital's CME activities will be commercially unbiased and based on scientific and clinical evidence. To help participants make judgments about the presence of commercial bias, Wills Eye Hospital provides information that planners and speakers have disclosed about financial relationships they have with commercial entities that produce, market, re-sell, or distribute health care goods or services consumed by, or used on, patients. All relevant financial relationships have been mitigated.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Dilru C Amarasekera, MD	Faculty, Peer Reviewer, Planner	Paid consultant-Microt (Relationship has ended)
Elizabeth Dale, MD	Faculty	Speakers Bureau-Sight Sciences|Speakers Bureau-Thea Pharmaceuticals
Jason Flamendorf, MD	Faculty	Nothing to disclose
Anfei Li, MD, PhD	Faculty	Nothing to disclose
Lindsay Machen, MD	Faculty	Nothing to disclose

Jonathan S. Myers, MD	Faculty	Stocks or stock options, excluding diversified mutual funds-Avisi|Grant or research support-Avisi|Stocks or stock options, excluding diversified mutual funds-Microt|Stocks or stock options, excluding diversified mutual funds-Olleyes|Grant or research support-AbbVie (Relationship has ended)|Grant or research support-Glaukos Corporation|Grant or research support-Nicox (Relationship has ended)|Grant or research support-Santen Pharmaceuticals (Relationship has ended)|Grant or research support-Guardian (Relationship has ended)|Grant or research support-Laboratories Thea Inc|Grant or research support-Ocular Therapeutix (Relationship has ended)|Grant or research support-Elios (Relationship has ended)|Grant or research support-PLU Ophthalmic (Relationship has ended)|Consulting Fee-Thea Labs|Honoraria-Glaukos Corporation
Rachel Niknam, MD	Faculty	Nothing to disclose
Michael Pro, MD	Faculty, Planner	Consulting Fee-Alcon (Relationship has ended)|Honoraria-Glaukos Corporation|Consulting Fee-New World Medical
Reza Razeghinejad, MD	Faculty	Grant or research support-Olleyes|Grant or research support-Equinox (Relationship has ended)
Jesse Richman, MD	Faculty	Consulting Fee-Alcon|Royalties or Patent Beneficiary-Visionology|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Visionology (Relationship has ended)|Paid consultant-Allergan (Relationship has ended)
Tina Xia, MD	Faculty	Grant or research support-AbbVie